Product Information
URSODIOL 300 MG CAPSULE is a generic product labeled by Strides Pharma Inc., priced at $0.4292 per EA under NDC 64380084406. Its NADAC has been published 211 times since Sep 21, 2022.
FDA first approved this application on Jan 22, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380084406
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
URSODIOLApproval Type
Generic (ANDA)
FDA Application
ANDA210344FDA Approved
1/22/2021
TE Code
AB
On Market Since
9/13/2021
Pharmacological Classes
Price Statistics
The NADAC for URSODIOL 300 MG CAPSULE has been published 211 times since Sep 21, 2022, and over the history we have for it it has declined 32.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4292 per EA |
|---|---|
| All-time high | $0.6902 (Dec 14, 2022) |
| All-time low | $0.3666 (Jul 17, 2024) |
| 52-week high | $0.4811 |
| 52-week low | $0.4160 |
| Median price | $0.4816 |
| Average price | $0.4961 |
| Largest weekly change | +30.7% (Aug 21, 2024) |
| Weeks tracked | 211 |
| Tracking since | Sep 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ursodiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ursodiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bile Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of URSODIOL 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for URSODIOL 300 MG CAPSULE, manufactured by Strides Pharma Inc., is $0.4292 per EA (NDC 64380084406), effective Sep 30, 2026.
How has the price of URSODIOL 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for URSODIOL 300 MG CAPSULE has declined 32.6%. It has been tracked across 211 weekly CMS publications since Sep 21, 2022.
What are the highest and lowest recorded NADAC prices for URSODIOL 300 MG CAPSULE?
Since Sep 21, 2022, the NADAC for URSODIOL 300 MG CAPSULE has ranged from a low of $0.3666 (Jul 17, 2024) to a high of $0.6902 (Dec 14, 2022), with a median of $0.4816 per EA.
Are there cheaper alternatives to URSODIOL 300 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of URSODIOL 300 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures URSODIOL 300 MG CAPSULE?
URSODIOL 300 MG CAPSULE (NDC 64380084406) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.